Prevention of stroke and systemic embolism in patients with atrial fibrillation: focus on apixaban


DOI: https://dx.doi.org/10.18565/therapy.2022.9.92-100

Kokorin V.A., Boeva O.I.

1) N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 2) Central State Medical Academy of Department of Presidential Affairs, Moscow
Abstract. This review of the literature data is dedicated to the choice of an oral anticoagulant for the prevention of ischemic stroke and systemic embolism in patients with atrial fibrillation. Detailed results of real-world clinical practice studies comparing the efficacy and safety of various direct oral anticoagulants are presented. Special attention is paid to groups of patients with atrial fibrillation and obesity, elderly and frail patients, as well as atrial fibrillation and impaired renal function.
Keywords: systemic embolism, direct oral anticoagulants, apixaban, bleeding, ischemic stroke, atrial fibrillation
Read entire article

Literature

1. Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498. https://dx.doi.org/10.1093/eurheartj/ehaa612.


2. Benjamin E.J., Wolf P.A., D’Agnostico R.B. et al. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation. 1998; 98(10): 946–52. https://dx.doi.org/10.1161/01.cir.98.10.946.


3. Wolf P.A., Dawber T.R., Thomas H.E., Kannel W.B. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978; 28(10): 973–77. https://dx.doi.org/10.1212/wnl.28.10.973.


4. Клинические рекомендации. Фибрилляция и трепетание предсердий у взрослых. Общероссийская общественная организация «Российское кардиологическое общество», Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и электростимуляции, Ассоциация сердечно-сосудистых хирургов России. Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 382. Доступ: https://cr.minzdrav.gov.ru/schema/382_1 (дата обращения – 01.11.2022). [Clinical guidelines. Atrial fibrillation and flutter in adults. Russian Society of Cardiology, All-Russian Scientific Society of Specialists in Clinical Electrophysiology, Arrhythmology and Electrical Stimulation, Association of Cardiovascular Surgeons of Russia. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. ID: 382.URL: https://cr.minzdrav.gov.ru/schema/382_1 (date of access – 01.11.2022) (In Russ.)].


5. Ezekowitz M.D., Bridgers S.L., James K.E. et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327(20): 1406–12. https://dx.doi.org/10.1056/NEJM199211123272002.


6. Hylek E.M. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost. 2013; 39(2): 147–52.https://dx.doi.org/10.1055/s-0033-1334812.


7. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–51. https://dx.doi.org/10.1056/NEJMoa0905561.


8. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–91. https://dx.doi.org/10.1056/NEJMoa1009638.


9. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–92. https://dx.doi.org/10.1056/NEJMoa1107039


10. Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–104. https://dx.doi.org/10.1056/NEJMoa1310907.


11. Harenberg J., Marx S., Diener H-C. et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol. 2012; 31(4): 330–39.


12. Larsen T.B., Skjoth F., Nielsen P.B. et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016; 353: i3189.https://dx.doi.org/10.1136/bmj.i3189.


13. Bai Y., Shi X.-B., Ma C.-S., Lip G.Y.H. Meta-analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban. Am J Cardiol. 2017; 120(9): 1689–95. https://dx.doi.org/10.1016/j.amjcard.2017.07.072.


14. Proietti M., Romanazzi I., Francesco Romiti G. et al. Real-world use of apixaban for stroke prevention in atrial fibrillation: A systematic review and meta-analysis. Stroke. 2018; 49(1): 98–106. https://dx.doi.org/10.1161/STROKEAHA.117.018395.


15. Lip G.Y.H., Keshishian A., Li X. et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018; 49(12): 2933–44. https://dx.doi.org/10.1161/STROKEAHA.118.020232.


16. Vinogradova Y., Coupland C., Hill T., Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018; 362: k2505. https://dx.doi.org/10.1136/bmj.k2505.


17. Chan Y.-H., Lee H.-F., See L.-C. et al. Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation. Chest. 2019; 156(3): 529–43. https://dx.doi.org/10.1016/j.chest.2019.04.108.


18. Graham D.J., Baro E., Zhang R. et al. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019; 132(5): 596–604.e11.https://dx.doi.org/10.1016/j.amjmed.2018.12.023.


19. Kjerpeseth L.J., Selmer R., Ariansen I. et al. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. PLoS One. 2019; 14(8): e0221500.https://dx.doi.org/10.1371/journal.pone.0221500.


20. Rutherford O.-C.W., Jonasson C., Ghanima W. et al. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: A nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2020; 6(2): 75–85.https://dx.doi.org/10.1093/ehjcvp/pvz086.


21. Jansson M., Sjalander S., Sjogren V. et al. Direct comparisons of effectiveness and safety of treatment with apixaban, dabigatran and rivaroxaban in atrial fibrillation. Thromb Res. 2020; 185: 135–41. https://dx.doi.org/10.1016/j.thromres.2019.11.010.


22. Ray W.A., Chung C.P., Stein C.M. et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021; 326(23): 2395–404. https://dx.doi.org/10.1001/jama.2021.21222.


23. Mamas M.A., Batson S., Pollock K.G. et al. Meta-analysis comparing apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation. Am J Cardiol. 2022; 166: 58–64. https://dx.doi.org/10.1016/j.amjcard.2021.11.021.


24. Lau W.C.Y., Torre C.O., Man K.K.C. et al. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: A multinational population-based cohort study. Ann Intern Med. 2022; 175(11): 1515–24. https://dx.doi.org/10.7326/M22-0511.


25. Schafer A., Flierl U., Berliner D., Bauersachs J. Anticoagulants for stroke prevention in atrial fibrillation in elderly patients. Cardiovasc Drugs Ther. 2020; 34(4): 555–68. https://dx.doi.org/10.1007/s10557-020-06981-3.


26. Bristol-Myers Squibb, Pfizer. Eliquis® (apixaban) Summary of product characteristics. 2017. URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf (date of access – 01.11.2022).


27. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa® (dabigatran etexilate) Prescribing Information. 2018. URL: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf (date of access – 01.11.2022).


28. Martinez B.K., Sood N.A., Bunz T.J., Coleman C.I. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018; 7(8): e008643. https://dx.doi.org/10.1161/JAHA.118.008643.


29. Okumura K., Yamashita T., Suzuki S., Akao M.; J-ELD AF Investigators. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry). Clin Cardiol. 2020; 43(3): 251–59. https://dx.doi.org/10.1002/clc.23294.


30. Martin K., Beyer–Westendorf J., Davidson B.L. et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14(6): 1308–13. https://dx.doi.org/10.1111/jth.13323.


31. Hohnloser S.H., Fudim M., Alexander J.H. et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation. 2019; 139(20): 2292–300. https://dx.doi.org/10.1161/CIRCULATIONAHA.118.037955.


32. O’Kane C.P., Avalon J.C.O., Lacoste J.L. et al. Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2. Pharmacotherapy. 2022; 42(2): 112–18. https://dx.doi.org/10.1002/phar.2651.


33. Bayer AG. Xarelto® (rivaroxaban) summary of product characteristics. 2018. URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf (date of access – 01.11.2022).


34. Daiichi Sankyo Europe GmbH. Lixiana® (edoxaban) summary of product characteristics. 2017. URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf (date of access – 01.11.2022).


About the Autors

Valentin A. Kokorin, Dr. med. habil., associate professor, professor of the Department of hospital therapy named after academician P.E. Lukomsky, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. Moscow. E-mail: valentinkokorin@yahoo.com. ORCID: https://orcid.org/0000-0001-8614-6542
Olga I. Boeva, Dr. med. habil., associate professor, professor of the Department of therapy, cardiology and functional diagnostics with the course of nefrology, Central State Medical Academy of Department of Presidential Affairs. Address: 121359, Moscow, 19/1A Marshala Timoshenko Str. E-mail: box0271@mail.ru.
ORCID: https://orcid.org/0000-0002-1816-8309


Similar Articles

Back to Content

Бионика Медиа